Skip to main content
. 2017 Feb 18;9(5):252–262. doi: 10.4254/wjh.v9.i5.252

Table 3.

Treatment tolerability (telaprevir)

Patients aged < 66 Patients aged ≥ 66 P value
Initial doses (median, range)
PEG-IFN/BW (μg/kg per week) 1.48 (0.98-2.00) 1.49 (1.15-1.87) 0.859
TVR/BW (mg/kg per day) 33.0 (19.2-64.3) 29.2 (7.5-54.2) 0.044
TVR (2250 mg/1500 mg/others), n 55/23/0 11/21/2 < 0.001
RBV/BW (mg/kg per day) 11.4 (6.8-20.0) 11.4 (5.7-28.0) 0.103
Dose reduction, n (%)
PEG-IFN 7 (8.9) 6 (17.6) 0.209
TVR 19 (24.3) 12 (35.3) 0.256
RBV 40 (51.2) 27 (79.4) 0.006
Discontinuation, n (%)
PEG-IFN 13 (16.7) 4 (11.8) 0.580
TVR 12 (15.4) 9 (26.5) 0.192
RBV 12 (15.4) 7 (20.6) 0.585
Adherence, mean ± SD (%)
PEG-IFN 88.2 ± 25.7 90.1 ± 19.8 0.606
TVR 88.8 ± 22.8 83.5 ± 25.5 0.103
RBV 79.3 ± 26.2 62.7 ± 25.3 < 0.001

PEG-IFN: Pegylated interferon; BW: Bodyweight; TVR: Telaprevir; RBV: Ribavirin.